Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.
Vistin Pharma ASA (VISTN) - Total Liabilities
Latest total liabilities as of June 2025: Nkr127.45 Million NOK
Based on the latest financial reports, Vistin Pharma ASA (VISTN) has total liabilities worth Nkr127.45 Million NOK as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vistin Pharma ASA - Total Liabilities Trend (2016–2024)
This chart illustrates how Vistin Pharma ASA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vistin Pharma ASA Competitors by Total Liabilities
The table below lists competitors of Vistin Pharma ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Onxeo SA
F:C4X
|
Germany | €26.19 Million |
|
FPX Nickel Corp
OTCQB:FPOCF
|
USA | $4.58 Million |
|
Satellogic Inc. Warrant
NASDAQ:SATLW
|
USA | $127.76 Million |
|
Seoul Viosys Co. Ltd
KQ:092190
|
Korea | ₩618.27 Billion |
|
BG Staffing Inc
NYSE:BGSF
|
USA | $32.89 Million |
|
Brinova Fastigheter AB (publ)
ST:BRIN-B
|
Sweden | Skr12.22 Billion |
|
Dexter Co Ltd
KQ:206560
|
Korea | ₩66.14 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Vistin Pharma ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vistin Pharma ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vistin Pharma ASA (2016–2024)
The table below shows the annual total liabilities of Vistin Pharma ASA from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr75.42 Million | -6.46% |
| 2023-12-31 | Nkr80.63 Million | -39.81% |
| 2022-12-31 | Nkr133.95 Million | +133.93% |
| 2021-12-31 | Nkr57.26 Million | +15.65% |
| 2020-12-31 | Nkr49.51 Million | -45.45% |
| 2019-12-31 | Nkr90.77 Million | -39.97% |
| 2018-12-31 | Nkr151.21 Million | +35.50% |
| 2017-12-31 | Nkr111.59 Million | +20.11% |
| 2016-12-31 | Nkr92.91 Million | -- |